Olympus Biotech names Oliver Burckhardt to president, North America

Olympus Biotech announced the appointment of Oliver Burckhardt to the position of president of Olympus Biotech Corporation. In his new role, Burckhardt will lead the company’s North American business and focus on expanding opportunities for the emerging regenerative medicine market, according to a company press release. Burckhardt will also become a member of the Olympus Biotech board of directors.

“With nearly 20 years in the medical device industry, Oliver’s extensive knowledge of the industry and global leadership experience will prove invaluable as we continue to grow Olympus Biotech,” Hitoshi Mizuno, chief executive officer of Olympus Biotech Corporation, stated in the release. “We look forward to benefiting from his immense expertise as we continue to lead the creation of this dynamic new field of medicine.”

Before joining Olympus Biotech, Burckhardt most recently served as the international president and chief executive officer of Scient’x Corp in Paris. Burckhardt also served as president of Orthofix Inc., where he was responsible for the global spine business unit. Prior to that, Burckhardt spent 9 years with Aesculap Inc. in various sales and marketing positions, including vice president of sales and marketing for the Aesculap Spine division in the United States.